Evidence map›Paper›PMID 23203961›Full record

ArticleAmerican journal of physiology. Heart and circulatory physiology2013

Nampt secreted from cardiomyocytes promotes development of cardiac hypertrophy and adverse ventricular remodeling.

Vinodkumar B Pillai, Nagalingam R Sundaresan, Gene Kim, Sadhana Samant, Liliana Moreno-Vinasco, Joe G N Garcia, Mahesh P Gupta

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Heart and circulatory physiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 94 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. eNAMPT Is a Novel DAMP and Therapeutic Target in Human and Murine Pulmonary Fibrosis.American journal of respiratory cell and molecular biology · 2025
    Article
  6. Review
  7. Article
  8. Review
  9. NAD metabolism and heart failure: Mechanisms and therapeutic potentials.Journal of molecular and cellular cardiology · 2024
    Review
  10. Article
  11. Article
  12. Review
  13. An eNAMPT-neutralizing mAb reduces post-infarct myocardial fibrosis and left ventricular dysfunction.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024
    Article
  14. Article
  15. Review
  16. Involvement of eNAMPT/TLR4 inflammatory signaling in progression of non-alcoholic fatty liver disease, steatohepatitis, and fibrosis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023
    Article
  17. Review
  18. Sex Differences in Adiposity and Cardiovascular Diseases.International journal of molecular sciences · 2022
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Vinodkumar B PillaiDepartment of Surgery, Section of Cardiothoracic Surgery, University of Chicago, Chicago, Illinois 60637, USA.
Nagalingam R Sundaresan
Gene Kim
Sadhana Samant
Liliana Moreno-Vinasco
Joe G N Garcia
Mahesh P Gupta
University of Chicago · USUniversity of Illinois Chicago · US

Funding

The Role of PARP-SIR2 Signaling in Heart FailureR01HL083423 · NHLBI · UNIVERSITY OF CHICAGO · PI GUPTA, MAHESH P · 2007 to 2011
$2.4M
Blocking cardiac toxicity of anticancer drugsR01HL117041 · NHLBI · UNIVERSITY OF CHICAGO · PI GUPTA, MAHESH P · 2013 to 2016
$1.8M
Activation of sirtuins to prevent adverse cardiac remodeling after CABGR01HL111455 · NHLBI · UNIVERSITY OF CHICAGO · PI GUPTA, MAHESH P · 2013 to 2016
$1.6M
NHLBI NIH HHS HL-111455NHLBI NIH HHS HL-83423NHLBI NIH HHS R01 HL111455NHLBI NIH HHS R01-HL-117041
6 · The paper itself

Abstract

Nicotinamide phosphoribosyltransferase (Nampt) is an important coenzyme involved in cellular redox reactions. Inside the cell, Nampt (iNampt) functions as a rate-limiting enzyme in the NAD salvage pathway, and outside the cell (eNampt), it acts as a proinflammatory cytokine. High-circulating levels of Nampt are reported in different pathological conditions. This study was designed to examine the role of Nampt in the development of cardiac hypertrophy and ventricular remodeling. We studied the hypertrophic response in Nampt heterozygous (+/-) knockout and cardiac-specific overexpressing Nampt transgenic mice. Whereas Nampt(+/-) mice were protected against agonist (isoproterenol and angiotensin II)-induced hypertrophy, Nampt transgenic mice spontaneously developed cardiac hypertrophy at 6 mo of age. Experiments conducted to gain insight into the mechanism revealed that treatment of cardiomyocytes with recombinant (eNampt) or overexpression with Nampt-synthesizing adenovirus vector (Ad.Nampt) induced cardiomyocyte hypertrophy. The prohypertrophic effects of eNampt and Ad.Nampt were blocked by the addition of a Nampt-blocking antibody into cultures, thus suggesting that Nampt was in fact invoking hypertrophic response of cardiomyocytes by acting on the cell surface receptors. We also found increased Nampt levels in the supernatant of cardiomyocyte cultures subjected to stress by either serum starvation or H(2)O(2) treatment. Exploration of signaling pathways in Nampt-induced cardiac hypertrophy and fibrosis revealed increased activation of mitogen-activated protein kinases, namely, JNK1, p38, and ERK. This was also associated with increased calcineurin levels and nuclear factor of activated T-cell localization into the nucleus. From these studies we conclude that cardiomyocytes are capable of secreting Nampt during stress, and exogenous Nampt is a positive regulator of cardiac hypertrophy and adverse ventricular remodeling.

Indexed as

AnimalsAnimals, NewbornCardiomegalyColoring AgentsEchocardiographyEnzyme-Linked Immunosorbent AssayFibroblastsFibrosisImmunohistochemistryLeucineMiceMice, KnockoutMice, TransgenicMitogen-Activated Protein KinasesMyocytes, CardiacNFATC Transcription FactorsColoring AgentsLeucineMitogen-Activated Protein KinasesNFATC Transcription FactorsNicotinamide PhosphoribosyltransferaseRNA, MessengerTetrazolium SaltsThiazolesthiazolyl blue

Identifiers

PMID23203961
PMCPMC3774498
OpenAlexW2123889798

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.